HOWARD CONSULTING GROUP, INC.

View full entity profile (contributions, contracts, SEC) →

Lobbying Income

$508K

Filings

Unique Clients

Active Period

2009–2019

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2019	$67,750	6	2
2018	$80,000	11	3
2017	$20,000	4	1
2016	$27,750	5	1
2015	$46,800	5	1
2014	$25,000	8	2
2013	$43,256	9	2
2012	$40,000	4	1
2011	$57,000	8	2
2010	$30,000	5	1
2009	$70,000	5	1

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
PHRMA (ON BEHALF OF WE WORK FOR HEALTH)	$385,930	48	2009–2019
PARATEK PHARMACEUTICALS	$42,750	5	2018–2019
INTERNET INFRASTRUCTURE COALITION	$36,876	9	2013–2014
NATIONAL MEDAL OF HONOR MUSEUM	$25,000	4	2018
RTI INTERNATIONAL	$17,000	4	2011

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	63
SENATE	60
Defense, Dept of (DOD)	4
Health & Human Services, Dept of (HHS)	4
Natl Institutes of Health (NIH)	4

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	53
Computer Industry	Computer Industry	8
Veterans	Veterans	5
Defense	Defense	5
Foreign Relations	Foreign Relations	4
Education	Education	4
Economics/Economic Development	Economics/Economic Development	3
Homeland Security	Homeland Security	3
Small Business	Small Business	1
Science/Technology	Science/Technology	1
Law Enforcement/Crime/Criminal Justice	Law Enforcement/Crime/Criminal Justice	1
Real Estate/Land Use/Conservation	Real Estate/Land Use/Conservation	1
Copyright/Patent/Trademark	Copyright/Patent/Trademark	1
Agriculture	Agriculture	1
Telecommunications	Telecommunications	1

Bills Explicitly Cited (12)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2010 · first_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry Senate Finance Committee options papers -H.R. 1427, Promoting Innovation & Access to Life-Saving Medicine Act; regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act; regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act; regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics

Client expense: — · Firm income: $10,000

Matched citations: H.R. 1427

H.R. 1548111th Congress

Pathway for Biosimilars Act

2010 · first_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry Senate Finance Committee options papers -H.R. 1427, Promoting Innovation & Access to Life-Saving Medicine Act; regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act; regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act; regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics

Client expense: — · Firm income: $10,000

Matched citations: H.R. 1548

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2010 · first_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry Senate Finance Committee options papers -H.R. 1427, Promoting Innovation & Access to Life-Saving Medicine Act; regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act; regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act; regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics

Client expense: — · Firm income: $10,000

Matched citations: S. 726

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · fourth_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -The "America's Healthy Futures Act of 2009"

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1427

Show 8 more cited filings

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · fourth_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -The "America's Healthy Futures Act of 2009"

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1548

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · fourth_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -The "America's Healthy Futures Act of 2009"

Client expense: — · Firm income: $20,000

Matched citations: S. 726

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · third_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -House Tri-Committee Health Reform Discussion draft -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -The "America's Healthy Futures Act of 2009"

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1427

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · third_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -House Tri-Committee Health Reform Discussion draft -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -The "America's Healthy Futures Act of 2009"

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1548

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · third_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -House Tri-Committee Health Reform Discussion draft -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -The "America's Healthy Futures Act of 2009"

Client expense: — · Firm income: $20,000

Matched citations: S. 726

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · second_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -House Tri-Committee Health Reform Discussion Draft -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics

Client expense: — · Firm income: $30,000

Matched citations: H.R. 1427

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · second_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -House Tri-Committee Health Reform Discussion Draft -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics

Client expense: — · Firm income: $30,000

Matched citations: H.R. 1548

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · second_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)

Open original LDA filing ↗

Cited source text and reported amounts

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -House Tri-Committee Health Reform Discussion Draft -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics

Client expense: — · Firm income: $30,000

Matched citations: S. 726

Source: Senate LDA

HOWARD CONSULTING GROUP, INC. — Lobbying Disclosure | Poliscope